Smart Model to Distinguish Crohn’s Disease from Ulcerative Colitis

Kasperczuk, Anna; Daniluk, Jarosław; Dardzińska, Agnieszka

doi:10.3390/app9081650

Cited by 6 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other models were constructive, including a logistic regression model. The analysis carried out in this work, as well as in another work, confirm the validity of the results obtained [27].…”

Section: Discussionsupporting

confidence: 88%

Differentiating Crohn’s Disease from Ulcerative Colitis - New Factors

Kasperczuk

Dardzińska

2019

BJSTR

Self Cite

View full text Add to dashboard Cite

Crohn's disease (CD) and ulcerative colitis (UC) have been known to physicians for decades. Unfortunately, so far there are many unknowns regarding CD and UC. There are numerous descriptions of clinical cases, different locations of disease symptoms, and descriptions of symptoms located both in the gastrointestinal tract and symptoms accompanying the disease.All this information sheds light on the etiology of inflammatory bowel disease (IBD) do not completely resolve their complexity. An analysis of the literature presented in the work indicates that the characteristics of diseases are often unambiguous. This contributes to the fact that IBD diagnostics are often difficult and create many problems [1][2][3]. Despite many years of research on inflammatory bowel diseases, they are still of interest to scientists today. Nonspecific inflammatory bowel disease is a term referring to chronic and recurrent gastrointestinal disease. A number of clinical symptoms distinguish between CD and UC, whose clinical picture is relatively diverse. However, in many cases the diagnosis is not straightforward, which contributes to the interest of researchers worldwide in the disorders under discussion. The inflammatory changes in the course of UC are continuous and limited to the mucous membrane of the large intestine. UC-related inflammation usually involves the mucosa and submucosa usually begins in the rectum and spread proximal to the colon. The affected tissue is swollen, with the presence of erosions and ulcers, which lead to spontaneous bleeding.In most cases, UC initially occurs smoothly, with worsening symptoms within a few weeks. It happens, however, that the disease begins suddenly and goes very quickly. In such cases, due to the lack of the effect of conservative treatment, surgical treatment is already implemented in the early stages of the disease. However, in most cases, after the first shot of the disease, it goes into remission, after which it becomes more severe again. Such continuous conditions of illness and remission may last even several dozen years [1,2]. In the case of CD, the condition most often includes the small intestine and caecum, which accounts for 40% of cases, only small intestine (30% of patients) and only large intestine (25% of cases). In situations where only the large intestine is covered, two forms of the disease are recognized. The first one concerns about two thirds of cases and consists in taking the entire length of the large intestine with the disease state, while the second involves the occurrence of staple

show abstract

Section: Discussionsupporting

confidence: 88%

Differentiating Crohn’s Disease from Ulcerative Colitis - New Factors

Kasperczuk

Dardzińska

2019

BJSTR

Self Cite

View full text Add to dashboard Cite

show abstract

“…Given that the TNBS-induced CD model has been unclear, focusing on distinguishing from ulcerative colitis . Here, we solved this fundamental problem.…”

Section: Discussionmentioning

confidence: 99%

“…Part of the difficulty in finding effective therapeutics for stenosis CD is the lack of a representative animal model that accurately simulates clinical practice. The trinitrobenzenesulfonic acid (TNBS)-induced colitis model in mouse with high recognition is often adopted in etiological and pharmacological study of CD; however, it is difficult to distinguish it from ulcerative colitis . In ulcerative colitis, inflammation is limited to the colonic and rectal mucosa and submucosa, while CD is characterized by transmural inflammation accompanied by cobblestone ulcers .…”

mentioning

confidence: 99%

Carboxymethyl Chitosan Oligosaccharide Holds Promise for Treatment of Stenosis Crohn’s Disease

Yuan

et al. 2022

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Crohn's disease (CD) is a chronic intestinal disturbance mediated by mucosal immune hyperactivity that is often associated with the formation of stenosis. No reliable solution to stenosis CD exists so far. Therefore, we generated carboxymethyl chitosan oligosaccharide (CMCOS) as a new promising therapy and investigate its efficacy in an improved rat CD model. CMCOS was synthesized by enzymatic hydrolysis, and its biosafety was evaluated in vivo. The rat model of stenosis CD was optimized by an orthogonal experiment of 75 or 100 mg/kg trinitrobenzenesulfonic acid (TNBS) in a 50 or 75% ethanol enema. The therapeutic efficacy of CMCOS on the rat model of stenosis CD was investigated and compared with the commercial drug 5-aminosalicylic acid over a 28 day period of disease progression. The rat model of stenosis CD was well established by intracolonic administration of 75 mg/kg TNBS in 75% ethanol. CMCOS significantly alleviated CD symptoms morphologically, hematologically, and pathologically, promoting functional recovery of intestinal epithelium in a dose-dependent manner. CMCOS reduced infiltrations of inflammatory cells by regulating the IL-17A/PPAR-γ pathway and reduced fibro-proliferation and fibrodegeneration of the colon tissue by downregulating the TGF-β1/WT1 pathway. 75 mg/kg TNBS in a 75% ethanol enema induces a rat model of stenosis CD suitable for preclinical pathology and pharmacological studies. The safety, antifibrosis, and functional repair performance of CMCOS make it a promising candidate for the treatment of stenosis CD.

show abstract

“…Laboratory examinations revealed the accumulation and activation of eosinophils in the active inflammatory intestinal mucosa in patients with UC and CD. However, there is a lack of accurate quantitative data and their possible distinction in the two diseases analysed in this paper (Kasperczuk et al, 2019;Merigo et al, 2018). Studies indicate that platelet count (PLT) often increases in association with active inflammation, and therefore may be a differentiating factor between UC and CD.…”

Section: Discussuionmentioning

confidence: 97%

Selected Morphotic Parameters Differentiating Ulcerative Colitis from Crohn’s Disease

Kasperczuk

2021

Acta Mechanica Et Automatica

Self Cite

View full text Add to dashboard Cite

This paper presents a method that binds statistical and data mining techniques, which aims to support the decision-making process in selected diseases of the digestive system. Currently, there is no precise diagnosis for ulcerative colitis (UC) and Crohn’s disease (CD). Specialist physicians must exclude many other diseases occurring in the colon. The first goal of this study is a retrospective analysis of medical data of patients hospitalised in the Department of Gastroenterology and Internal Diseases, Bialystok, and finding the symptoms differentiating the two analysed diseases. The second goal is to build a system that clearly points to one of the two diseases UC or CD, which shortens the time of diagnosis and facilitates the future treatment of patients. The work focuses on building a model that can be the basis for the construction of action rules, which are one of the basic elements in the medical recommendation system. Generated action rules indicated differentiating factors, such as mean corpuscular volume, platelets (PLTs), neutrophils, monocytes, eosinophils, basophils, alanine aminotransferase (ALAT), creatinine, sodium and potassium. Other important parameters were smoking and blood in stool.

show abstract

Smart Model to Distinguish Crohn’s Disease from Ulcerative Colitis

Cited by 6 publications

References 32 publications

Differentiating Crohn’s Disease from Ulcerative Colitis - New Factors

Differentiating Crohn’s Disease from Ulcerative Colitis - New Factors

Carboxymethyl Chitosan Oligosaccharide Holds Promise for Treatment of Stenosis Crohn’s Disease

Selected Morphotic Parameters Differentiating Ulcerative Colitis from Crohn’s Disease

Contact Info

Product

Resources

About